# How do CJC-1295, sermorelin and ipamorelin differ? Updated 2026-10-16. CJC-1295 and sermorelin are lab-made relatives of growth-hormone-releasing hormone (GHRH), a natural signal. Ipamorelin works through a different receiver on cells, the growth hormone secretagogue receptor. The CJC-1295 described by Jetté and colleagues also grips albumin, a blood protein. These differences sort the compounds into research groups. Separate studies do not show the effects or safety of a mix of all three. | | | | --- | --- | | CJC-1295 family | Modified growth-hormone-releasing factor; albumin-binding design (Jetté et al., 2005) | | Sermorelin identity | GHRH analogue of 29 amino acids (Prakash and Goa, 1999) | | Ipamorelin structure | Peptide of five amino acids (Raun et al., 1998) | | Comparison basis | Receptor pathway, molecular design and measured results | | Shared-preparation evidence | Not established by the separate studies cited here | Even while you sit still, your glands pass messages through your blood. A message needs the right receiver before a cell can respond. Growth hormone research follows several of these message routes, which helps explain why similar-looking compound names can describe different molecules. [The ipamorelin hub](/learn/ipamorelin) connects the questions behind this comparison. A search for sermorelin, ipamorelin and CJC-1295 can mean a comparison, or a preparation that contains all three. This page compares the separate compounds. Seeing their names side by side does not turn separate experiments into evidence about a mixture. ## Can separate studies show how the three compounds compare? Separate studies of CJC-1295, sermorelin and ipamorelin cannot show which compound is better. They also cannot show how a mix of them behaves. Each human paper opened for this page asked a different question in a different group of people. Teichman and colleagues studied CJC-1295 hormone responses in healthy adults. Gobburu and colleagues modelled ipamorelin levels and growth hormone responses in healthy men. Losa and colleagues compared growth-hormone-releasing factor fragments with placebo, a dummy treatment. None of these studies tested all the named compounds against each other. And a change in a blood marker cannot, on its own, show a change in health. A fair comparison needs matching groups and a shared endpoint. An endpoint is the specific result a study measures. A hormone peak, time in the blood and a health outcome answer different questions. [The ipamorelin evidence overview](/learn/ipamorelin/what-is-ipamorelin) separates lab findings from human studies. ## Do CJC-1295, sermorelin and ipamorelin act on the same receptor? CJC-1295 and sermorelin use the growth-hormone-releasing hormone (GHRH) pathway. Ipamorelin uses a separate route, the secretagogue receptor pathway. A receptor is a protein on a cell that receives a chemical message, a bit like a lock that only one shape of key fits. GHRH is one natural signal involved in growth hormone release. Howard and colleagues identified the separate secretagogue receptor. Kojima and colleagues later identified ghrelin, a natural signal for that receptor. Raun and colleagues linked ipamorelin to the secretagogue route in rat and pig experiments. These experiments tell the pathways apart. They do not show what a mix would do in people. The pituitary is a small gland below the brain that releases growth hormone. Different chemical messages can reach the same gland through different receivers, like two doors into one room. Ending at the same hormone does not make the starting molecules the same. ![Two separate arrows dock into two different receptors on one gland labelled "Pituitary gland": one labelled "GHRH receptor", one labelled "Secretagogue receptor"; one arrow leaves the gland labelled "Growth hormone".](/assets/content/edu-two-receptor-pathways-one-gland.png) CJC-1295 and sermorelin belong to the GHRH receptor pathway; ipamorelin belongs to the separate secretagogue receptor pathway (Jetté et al., 2005; Prakash and Goa, 1999; Raun et al., 1998). The picture shows receptor categories, not evidence about a mixture. ## How is CJC-1295 different from sermorelin? CJC-1295 differs from sermorelin in two ways: changes to its structure, and a part that grips albumin. Sermorelin is a short lab-made relative of GHRH, as Prakash and Goa describe. Jetté and colleagues described CJC-1295 as a modified GHRH fragment. It carries an added chemical group that binds albumin, a protein in the blood. Their paper tested cells and rats. Albumin binding helps explain why the CJC-1295 they studied stays in the blood longer, a little like a small passenger riding on a large bus. These lab findings show a design difference. They do not rank the compounds by health outcome or show equal safety. The name on a page must match the molecule in the paper. A CJC-1295 label alone does not prove that a material has the albumin-binding part that Jetté and colleagues studied. That part is called DAC, short for drug affinity complex. [The CJC-1295 DAC identity explainer](/learn/peptide-quality-verification/cjc-1295-dac-vs-no-dac) covers this naming problem. ## What have human studies measured for these compounds? The human studies cited here measured hormone responses. For CJC-1295 and ipamorelin, they also measured how the compounds behave in the blood. Teichman and colleagues reported lasting changes in growth hormone and in insulin-like growth factor I in healthy adults. Insulin-like growth factor I, often shortened to IGF-I, is another hormone. Gobburu and colleagues measured ipamorelin levels in the blood and a brief growth hormone response. Losa and colleagues recorded growth hormone responses to GHRH fragments. These results describe the settings that were tested. They do not show a shared health outcome. Time in the blood and the timing of a hormone response are separate measurements. A compound can fade from the blood while another part of the signal stays changed. [The CJC-1295 time-course explainer](/learn/cjc-1295/cjc-1295-pharmacokinetics) covers that difference. A longer signal describes timing. It is not a measure of value. ## Does receptor selectivity show which compound is safer? Receptor selectivity does not show that CJC-1295, sermorelin or ipamorelin is safer than the others. Selectivity describes which signals a compound affects under the tested conditions. Raun and colleagues studied ipamorelin's hormone profile in pigs. In that setting, the stress-hormone measurements ACTH and cortisol did not differ significantly from the responses to GHRH. ACTH is a signal that tells the body to release cortisol. A pig result cannot show human safety. A real safety comparison would need direct evidence about harmful events in matching groups of people, including how long they were followed. A study that reports no serious adverse events still has limits: who took part, what conditions were tested and how long people were watched. Missing evidence is not evidence of no risk. [The ipamorelin safety evidence page](/learn/ipamorelin/ipamorelin-side-effects) explains the gaps. The papers cited here do not show the safety or effects of a preparation that contains all the compared compounds. ## Comparison Each compound on its own, compared by the receptor it uses, how the molecule is built and one example of what was measured. The table does not rank outcomes or describe a mix. | Compound | Receptor category | Design difference | Evidence example | | --- | --- | --- | --- | | CJC-1295 | GHRH receptor | GHRH analogue that binds albumin (Jetté et al., 2005) | Hormone markers and time in the blood in healthy adults (Teichman et al., 2006) | | Sermorelin | GHRH pathway | Short GHRH analogue (Prakash and Goa, 1999) | Hormone responses to GHRH fragments in volunteers (Losa et al., 1984) | | Ipamorelin | Secretagogue receptor | Different peptide family (Raun et al., 1998) | Blood levels and growth hormone response in healthy men (Gobburu et al., 1999) | ## Frequently asked questions ### Are sermorelin and ipamorelin the same thing? No. Sermorelin and ipamorelin are different peptides. Sermorelin uses the GHRH pathway, and ipamorelin uses the secretagogue pathway. Both are measured through growth hormone, but that does not make them interchangeable. ### Is CJC-1295 the same as sermorelin? No. CJC-1295 and sermorelin are both related to GHRH, but their structures differ. The CJC-1295 studied by Jetté and colleagues includes changes and an albumin-binding group. Findings about that molecule cannot prove what a material with a similar label contains. ### Does research establish the effects of all three together? No. The separate papers cited on this page do not show the effects or safety of a preparation that contains CJC-1295, sermorelin and ipamorelin together. A receptor diagram cannot replace a study of the exact preparation. These sources leave the combined effects unconfirmed. ## Citations - Jetté L, Léger R, Thibaudeau K, et al.. Endocrinology. 2005;146(7):3052-3058. DOI: 10.1210/en.2004-1286 - Teichman SL, Neale A, Lawrence B, et al.. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. DOI: 10.1210/jc.2005-1536 - Raun K, Hansen BS, Johansen NL, et al.. European Journal of Endocrinology. 1998;139(5):552-561. DOI: 10.1530/eje.0.1390552 - Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmaceutical Research. 1999;16(9):1412-1416. DOI: 10.1023/a:1018955126402 - Losa M, Schopohl J, Müller OA, von Werder K. Klinische Wochenschrift. 1984;62(23):1140-1143. DOI: 10.1007/BF01782473 - Prakash A, Goa KL. BioDrugs. 1999;12(2):139-157. DOI: 10.2165/00063030-199912020-00007 - Howard AD, Feighner SD, Cully DF, et al.. Science. 1996;273(5277):974-977. DOI: 10.1126/science.273.5277.974 - Kojima M, Hosoda H, Date Y, et al.. Nature. 1999;402(6762):656-660. DOI: 10.1038/45230 [Explore the ipamorelin learning hub](/learn/ipamorelin) [Read the CJC-1295 overview](/learn/cjc-1295/what-is-cjc-1295) --- Canonical page: https://www.formlaboratories.com/learn/ipamorelin/cjc-1295-sermorelin-ipamorelin Form Laboratories - Perth-based research-use-only peptide supplier, shipping Australia-wide. - Site guide for agents: https://www.formlaboratories.com/llms.txt - Sitemap: https://www.formlaboratories.com/sitemap.xml - Full catalogue: https://www.formlaboratories.com/shop - Contact: hello@formlaboratories.com All materials are supplied for laboratory research use only - not for human or veterinary use, and nothing on this site is medical advice.